Tilray, Inc. TLRY reported fourth-quarter losses at $2.14 per share, which does not compare to the 35-cent loss estimate. The company reported sales $46.936 million, which missed the analysts estimate of $55.92 million.
Tilray reported fourth-quarter total cannabis kilogram equivalents sold 15.039K kg and adjusted EBITDA loss of $35.3 million.
"Our full year results demonstrate strong sales growth momentum, which we expect to continue in 2020," said CEO Brendan Kennedy. "Like our peers, we have faced industry challenges, but we remain committed to driving long-term value for our shareholders. Tilray has a diversified business model comprised of global medical, Canada adult-use and hemp products which positions us well in the current volatile market environment."
Latest Startup Investment Opportunities:
Tilray's stock was down 10% in Monday's after-hours session after closing at $15.25 per share. The stock has a 52-week high of $82.81 and a 52-week low of $13.20.
Related Links:
Tilray, Aurora Cannabis Layoffs May Signal Industrywide Problem
Digesting What Cannabis 2.0 Means For The Industry: 'A Lot Of Opportunity'
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!
